• 1
    Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J. Clin. Invest. 2012; 122: 27492755.
  • 2
    Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J. 2006; 28: 219242.
  • 3
    Bathoorn E, Kerstjens H, Postma D et al. Airways inflammation and treatment during acute exacerbations of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2008; 3: 217229.
  • 4
    Rahman I, Biswas SK. Non-invasive biomarkers of oxidative stress: reproducibility and methodological issues. Redox. Rep. 2004; 9: 125143.
  • 5
    Hillas G, Loukides S, Kostikas K et al. Biomarkers obtained by non-invasive methods in patients with COPD: where do we stand, what do we expect? Curr. Med. Chem. 2009; 16: 28242838.
  • 6
    Barnes PJ, Chowdhury B, Kharitonov SA et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 614.
  • 7
    Lärstad M, Ljungkvist G, Olin AC et al. Determination of malondialdehyde in breath condensate by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002; 766: 107114.
  • 8
    Corradi M, Rubinstein I, Andreoli R et al. Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 167: 13801386.
  • 9
    Bartoli ML, Novelli F, Costa F et al. Malondialdehyde in exhaled breath condensate as a marker of oxidative stress in different pulmonary diseases. Mediators Inflamm. 2011; 891752 17.
  • 10
    Corradi M, Pignatti P, Manini P et al. Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation. Eur. Respir. J. 2004; 24: 10111017.
  • 11
    Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532555.
  • 12
    Antus B, Barta I, Kullmann T et al. Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: a longitudinal study. Am. J. Respir. Crit. Care Med. 2010; 182: 14921497.
  • 13
    Antus B, Barta I, Csiszer E et al. Exhaled breath condensate pH in patients with cystic fibrosis. Inflamm. Res. 2012; 61: 11411147.
  • 14
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307310.
  • 15
    Corradi M, Folesani G, Andreoli R et al. Aldehydes and glutathione in exhaled breath condensate of children with asthma exacerbation. Am. J. Respir. Crit. Care Med. 2003; 167: 395399.
  • 16
    Franklin P, Moeller A, Hall GL et al. Variability of nitric oxide metabolites in exhaled breath condensate. Respir. Med. 2006; 100: 123129.
  • 17
    Borrill ZL, Starkey RC, Singh SD. Variability of exhaled breath condensate leukotriene B4 and 8-isoprostane in COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2007; 2: 7176.
  • 18
    Kullmann T, Barta I, Antus B et al. Drinking influences exhaled breath condensate acidity. Lung 2008; 186: 263268.
  • 19
    Giera M, Lingeman H, Niessen WM. Recent advancements in the LC- and GC-based analysis of malondialdehyde (MDA): a brief overview. Chromatographia 2012; 75: 433440.
  • 20
    Bathoorn E, Liesker J, Postma D et al. Safety of sputum induction during exacerbations of COPD. Chest 2007; 131: 432438.